|
ANXA5 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 5.68319946658846E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.56069995710584E-09 |
| Normal-vs-Stage2 |
1.272570E-01 |
| Normal-vs-Stage3 |
2.02609999999659E-06 |
| Normal-vs-Stage4 |
9.14669999962925E-07 |
| Stage1-vs-Stage2 |
1.897960E-01 |
| Stage1-vs-Stage3 |
9.522000E-01 |
| Stage1-vs-Stage4 |
6.998400E-01 |
| Stage2-vs-Stage3 |
2.292000E-01 |
| Stage2-vs-Stage4 |
1.506400E-01 |
| Stage3-vs-Stage4 |
7.032800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.55090000234048E-08 |
| Normal-vs-AfricanAmerican |
1.095530E-03 |
| Normal-vs-Asian |
2.32119999887814E-08 |
| Caucasian-vs-AfricanAmerican |
4.914400E-02 |
| Caucasian-vs-Asian |
8.971500E-04 |
| AfricanAmerican-vs-Asian |
6.784000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.73169999999812E-05 |
| Normal-vs-Female |
5.50140044630609E-10 |
| Male-vs-Female |
3.963200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.14159998016095E-09 |
| Normal-vs-Age(41-60Yrs) |
1.87109999716384E-08 |
| Normal-vs-Age(61-80Yrs) |
2.216300E-02 |
| Normal-vs-Age(81-100Yrs) |
1.199780E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.710000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.821000E-03 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.184800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.193500E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.281200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.241600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.177000E-01 |
| Classical-VS-Follicular |
2.48720044560002E-10 |
| Classical-VS-Other |
9.240100E-02 |
| Classical-VS-Normal |
5.99520433297585E-14 |
| Tall-VS-Follicular |
9.563800E-04 |
| Tall-VS-Other |
1.385810E-01 |
| Tall-VS-Normal |
6.09320000000135E-05 |
| Follicular-VS-Other |
6.884400E-01 |
| Follicular-VS-Normal |
9.965600E-01 |
| Other-VS-Normal |
7.311000E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.122670E-03 |
| Normal-vs-N1 |
1.956010E-04 |
| N0-vs-N1 |
7.982400E-02 |
|
|
